ABSTRACT
BACKGROUND: Regulatory CD4+ T cells (Tregs) exhibit functional alterations in patients with multiple sclerosis (MS). Transforming growth factor (TGF)-ß is a key regulator of Treg development and function. OBJECTIVE: The objective of this study is to determine whether the expression of functionally relevant TGF-ß-regulated molecules is altered in Tregs from patients with MS. METHODS: Expression of nine Treg markers was analyzed by multi-color flow cytometry in CD4+ T cells and Treg subpopulations of 31 untreated MS patients and age- and sex-matched healthy donors (HDs). Correlations between Treg marker expression and clinical variables were sought. RESULTS: Expression of the transcription factor Helios, which defines thymic-derived Tregs, was decreased in this Treg subpopulation. The frequency of peripherally generated Tregs was increased in patients with MS, particularly in patients with progressive MS. Low frequencies of thymic-derived Tregs were associated with magnetic resonance imaging (MRI) lesion-burden and a high relapse rate. Four surface markers associated with TGF-ß signaling (ABCA1, BTLA, DNAM-1, and GARP) were differentially expressed on Tregs from patients with MS and HDs. Expression levels of CD73, CD103, ABCA1, and PAR2 showed strong correlations with disease severity. CONCLUSION: We have identified novel markers abnormally expressed on Tregs from patients with MS that could detect patients with severe disease.
Subject(s)
Multiple Sclerosis , T-Lymphocytes, Regulatory , Cells, Cultured , Flow Cytometry , Gene Expression Regulation , HumansABSTRACT
PURPOSE: To investigate the efficacy of metformin (M) plus chemotherapy versus chemotherapy alone in metastatic breast cancer (MBC). METHODS: Non-diabetic women with HER2-negative MBC were randomized to receive non-pegylated liposomal doxorubicin (NPLD) 60 mg/m2 + cyclophosphamide (C) 600 mg/m2 × 8 cycles Q21 days plus M 2000 mg/day (arm A) versus NPLD/C (arm B). The primary endpoint was progression-free survival (PFS). RESULTS: One-hundred-twenty-two patients were evaluable for PFS. At a median follow-up of 39.6 months (interquartile range [IQR] 24.6-50.7 months), 112 PFS events and 71 deaths have been registered. Median PFS was 9.4 months (95% CI 7.8-10.4) in arm A and 9.9 (95% CI 7.4-11.5) in arm B (P = 0.651). In patients with HOMA index < 2.5, median PFS was 10.4 months (95% CI 9.6-11.7) versus 8.5 (95% CI 5.8-9.7) in those with HOMA index ≥ 2.5 (P = 0.034). Grade 3/4 neutropenia was the most common toxicity, occurring in 54.4% of arm A patients and 72.3% of the arm B group (P = 0.019). M induced diarrhea (G2) was observed in 8.8% of patients in Arm A. The effect of M was similar in patients with HOMA index < 2.5 and ≥ 2.5, for PFS and OS. CONCLUSIONS: The MYME trial failed to provide evidence in support of an anticancer activity of M in combination with first line CT in MBC. A significantly shorter PFS was observed in insulin-resistant patients (HOMA ≥ 2.5). Noteworthy, M had a significant effect on CT induced severe neutropenia. Further development of M in combination with CT in the setting of MBC is not warranted.
Subject(s)
Breast Neoplasms/drug therapy , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Metformin/administration & dosage , Receptor, ErbB-2/deficiency , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/metabolism , Breast Neoplasms/mortality , Cyclophosphamide/adverse effects , Doxorubicin/adverse effects , Drug Administration Schedule , Drug Therapy , Female , Humans , Metformin/adverse effects , Middle Aged , Progression-Free Survival , Survival Analysis , Treatment OutcomeABSTRACT
PURPOSE: Metronomic oral vinorelbine (MOV) could be a treatment option for unfit patients with advanced non-small cell lung cancer (NSCLC) based on its safety profile and high patient compliance. METHODS: We retrospectively collected data on 270 patients [median age 76 (range 48-92) years, M/F 204/66, PS 0 (27)/1 (110)/≥ 2 (133), median of 3 serious comorbidities] with stage IIIB-IV NSCLC treated with MOV as first (T1) (67%), second (T2) (19%) or subsequent (T3) (14%) line. Schedules consisted of vinorelbine 50 mg (138), 40 mg (68) or 30 mg (64) three times a week continuously. RESULTS: Patients received an overall median of 6 (range 1-25) cycles with a total of 1253 cycles delivered. The overall response rate was 17.8% with 46 partial and 2 complete responses and 119 patients (44.1%) experienced stable disease > 12 weeks with an overall disease control rate of 61.9%. Median overall time to progression was 5 (range 1-21) months [T1 7 (1-21), T2 5.5 (1-19) and T3 4 (1-19) months] and median overall survival 9 (range 1-36) months [T1 10 (1-31), T2 8 (1-36) and T3 6.5 (2-29) months]. Treatment was extremely well tolerated with 2% (25/1253) G3/4 toxicity (mainly G3 fatigue and anemia) and no toxic deaths. We observed the longer OS 14 (range 7-36) months in a subset of squamous NSCLC patients receiving immunotherapy after metronomic oral vinorelbine. CONCLUSION: We confirmed MOV as an extremely safe treatment in a large real world population of advanced NSCLC with an interesting activity mainly consisting of long-term disease stabilization. We speculate the possibility of a synergistic effect with subsequent immunotherapy.
Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Agents, Phytogenic/administration & dosage , Carcinoma, Large Cell/drug therapy , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Squamous Cell/drug therapy , Lung Neoplasms/drug therapy , Vinorelbine/administration & dosage , Adenocarcinoma/pathology , Administration, Metronomic , Aged , Aged, 80 and over , Carcinoma, Large Cell/pathology , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Squamous Cell/pathology , Female , Follow-Up Studies , Humans , International Agencies , Lung Neoplasms/pathology , Male , Middle Aged , Palliative Care , Remission Induction , Retrospective Studies , Survival RateABSTRACT
OBJECTIVE: To describe and compare the clinical impacts of neurocysticercosis (NC) caused by Taenia solium in humans and pigs. METHODS: Comparative study of the brains of 16 asymptomatic pigs and 35 human NC cases (15 asymptomatic and 20 symptomatic). RESULTS: In humans, cysticerci were more frequently located in the ventricles and subarachnoid space at the base of the brain (11.8%vs. 1.6%; P = 0.001 and 25.9%vs. 0%; P < 0.0001, respectively) while in pigs, cysticerci were more frequently found in the parenchyma (44.4%vs. 7.6%; P < 0.0001). In human brains, 75.9% of the cysticerci were calcified, while in pigs all cysticerci were in the vesicular stage. CONCLUSION: The duration of infection and the host-parasite relationship (such as immune reactivity and brain haemodynamics) differ between humans and pigs. This may account for the different distribution and stage of the cysticerci among humans and pigs.
Subject(s)
Brain Diseases/parasitology , Neurocysticercosis/parasitology , Swine Diseases/parasitology , Taenia solium/growth & development , Animals , Brain/parasitology , Brain Diseases/veterinary , Cysticercus/growth & development , Cysticercus/isolation & purification , Humans , Magnetic Resonance Imaging , Neurocysticercosis/veterinary , Swine , Taenia solium/isolation & purificationABSTRACT
The distribution of single cysticerci between cerebral hemispheres was studied in 227 adult cases of calcified and vesicular neurocysticercosis (NC). A rightward lateralization of calcified cysticerci was significant only in women, whereas vesicular cysticerci were equally distributed in both hemispheres. Factors related with the differences in the inflammatory response and in the regional cerebral blood flow between genders could be involved.
Subject(s)
Cerebrum/parasitology , Cysticercus/isolation & purification , Neurocysticercosis/diagnostic imaging , Neurocysticercosis/parasitology , Taenia/isolation & purification , Animals , Cerebrum/diagnostic imaging , Female , Humans , Magnetic Resonance Imaging , Male , Sex Factors , Tomography, X-Ray ComputedABSTRACT
Allelic frequencies of 15 short tandem repeats (STR) markers (CSF1PO, FGA, THO1, TPOX, VWA, D3S11358, D5S818, D7S820, D8S1179, D13S317, D16S539, D18S51, D21S11, D19S433 and D2S1338) were determined using the AmpFl STR Identifiler PCR Amplification Kit in Puerto Rican American individuals (N=205) from Massachusetts. The FGA, D18S51 and D2S1338 loci had a high power of discrimination (PD) with values of 0.967, 0.965 and 0.961, respectively. Significant deviations from the Hardy-Weinberg (HW) equilibrium were not detected. An important genetic contribution of Caucasian European (76.4%) was detected in Puerto Rican Americans. However, comparative analysis between Puerto Rican American and other neighboring populations from United States mainly with African and Caucasian Americans, revealed significant differences in the distribution of STR markers. Our results are important for future comparative genetic studies of different American ethnic groups, in particular a cultural group called Hispanic-Americans and should be helpful for forensic and paternity testing.
Subject(s)
Gene Frequency , Genetics, Population , Hispanic or Latino/genetics , Tandem Repeat Sequences , DNA Fingerprinting , Humans , Massachusetts , Polymerase Chain Reaction , Puerto Rico/ethnologyABSTRACT
Influenza vaccination is a key intervention to reduce morbidity and mortality provoked by this disease. To date, the challenge of improving its efficacy remains unmet. The immunogenic synthetic peptide GK1 from Taenia crassiceps cysticerci was tested herein in its capacity as adjuvant, co-administered with the inactivated anti-influenza vaccine before and after challenge with influenza virus in both young and aged mice. Co-administration of GK1 with the influenza vaccine increased levels of anti-influenza antibodies in aged mice before and after infection, reduced the local inflammation that accompanied influenza vaccination itself and favored virus clearance after infection in both young and aged mice.
Subject(s)
Adjuvants, Immunologic/pharmacology , Influenza Vaccines/immunology , Peptides/pharmacology , Aluminum Hydroxide/pharmacology , Amino Acid Sequence , Animals , Antibodies, Viral/blood , Female , Immunoglobulin G/blood , Lung/pathology , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Saponins/pharmacology , VaccinationABSTRACT
Pain is a highly distressing symptom for patients with advanced cancer. WHO analgesic ladder is widely accepted as a guideline for its treatment. Our aim was to describe pain prevalence among patients diagnosed with advanced non-small-cell lung cancer (NSCLC), impact of pain on quality of life (QoL) and adequacy of pain management. Data of 1021 Italian patients enrolled in three randomised trials of chemotherapy for NSCLC were pooled. QoL was assessed by EORTC QLQ-C30 and LC-13. Analgesic consumption during the 3 weeks following QoL assessment was recorded. Adequacy of pain management was evaluated by the Pain Management Index (PMI). Some pain was reported by 74% of patients (42% mild, 24% moderate and 7% severe); 50% stated pain was affecting daily activities (30% a little, 16% quite a bit, 3% very much). Bone metastases strongly affected presence of pain. Mean global QoL linearly decreased from 64.9 to 36.4 from patients without pain to those with severe pain (P<0.001). According to PMI, 616 out of 752 patients reporting pain (82%) received inadequate analgesic treatment. Bone metastases were associated with improved adequacy and worst pain with reduced adequacy at multivariate analysis. In conclusion, pain is common in patients with advanced NSCLC, significantly affects QoL, and is frequently undertreated. We recommend that: (i). pain self-assessment should be part of oncological clinical practice; (ii). pain control should be a primary goal in clinical practice and in clinical trials; (iii). physicians should receive more training in pain management; (iv). analgesic treatment deserves greater attention in protocols of anticancer treatment.
Subject(s)
Carcinoma, Non-Small-Cell Lung/complications , Lung Neoplasms/complications , Pain Management , Pain/epidemiology , Adult , Aged , Aged, 80 and over , Bone Neoplasms/complications , Bone Neoplasms/secondary , Carcinoma, Non-Small-Cell Lung/secondary , Female , Humans , Italy , Lung Neoplasms/pathology , Male , Middle Aged , Pain/etiology , Pain Measurement , Prevalence , Quality of Life , Randomized Controlled Trials as Topic , Severity of Illness IndexABSTRACT
The present study describes supportive care (SC) in patients with advanced non-small-cell lung cancer (NSCLC), evaluating whether it is affected by concomitant chemotherapy, patient's performance status (PS) and age. Data of patients enrolled in three randomised trials of first-line chemotherapy, conducted between 1996 and 2001, were pooled. The analysis was limited to the first three cycles of treatment. Supportive care data were available for 1185 out of 1312 (90%) enrolled patients. Gastrointestinal drugs (45.7%), corticosteroids (33.4%) and analgesics (23.8%) were the most frequently observed categories. The mean number of drugs per patient was 2.43; 538 patients (45.4%) assumed three or more supportive drugs. Vinorelbine does not produce substantial variations in the SC pattern, while cisplatin-based treatment requires an overall higher number of supportive drugs, with higher use of antiemetics (41 vs 27%) and antianaemics (10 vs 4%). Patients with worse PS are more exposed to corticosteroids (42 vs 30%). Elderly patients require drugs against concomitant diseases significantly more than adults (20 vs 7%) and are less frequently exposed to antiemetics (12 vs 27%). In conclusion, polypharmacotherapy is a relevant issue in patients with advanced NSCLC. Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Deoxycytidine/analogs & derivatives , Lung Neoplasms/drug therapy , Vinblastine/analogs & derivatives , Adult , Aged , Aged, 80 and over , Aging , Antiemetics/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/secondary , Cisplatin/administration & dosage , Deoxycytidine/administration & dosage , Female , Humans , Lung Neoplasms/pathology , Lung Neoplasms/secondary , Male , Middle Aged , Palliative Care , Quality of Life , Randomized Controlled Trials as Topic , Survival Rate , Vinblastine/administration & dosage , Vinorelbine , GemcitabineABSTRACT
AIMS AND BACKGROUND: In addition to nausea and vomiting following chemotherapy treatment, cancer patients can experience these side effects prior to a treatment session, the so-called anticipatory nausea and vomiting. As various psychological and neurophysiological aspects have been claimed to be implied in its etiopathogenesis, the present paper aims to shortly review the etiological, epidemiological and therapeutical assumptions on the topic, in particular the psychological-behavioral therapies. PATIENTS AND METHODS: The present study was carried out on 16 consecutive adult cancer patients affected by chemotherapy-induced anticipatory nausea and vomiting who had received at least four treatment cycles. All of them were submitted to induction of relaxation followed by hypnosis. RESULTS: In all subjects anticipatory nausea and vomiting disappeared, and major responses to chemotherapy-induced emesis control were recorded in almost all patients. CONCLUSIONS: The experience highlights the potential value of hypnosis in the management of anticipatory nausea and vomiting; furthermore, the susceptibility to anticipatory nausea and vomiting is discussed under the psychoanalytic point of view.
Subject(s)
Hypnosis , Nausea/therapy , Neoplasms/complications , Vomiting, Anticipatory/therapy , Adult , Aged , Drug-Related Side Effects and Adverse Reactions , Female , Humans , Male , Middle Aged , Nausea/etiology , Neoplasms/drug therapy , Vomiting, Anticipatory/etiologyABSTRACT
CONTEXT: Botulism is an important public health problem in Argentina, but obtaining antitoxin rapidly has been difficult because global supplies are limited. In January 1998, a botulism outbreak occurred in Buenos Aires. OBJECTIVES: To determine the source of the outbreak, improve botulism surveillance, and establish an antitoxin supply and release system in Argentina. DESIGN, SETTING, AND PARTICIPANTS: Cohort study in January 1998 of 21 drivers of a specific bus route in urban Buenos Aires. MAIN OUTCOME MEASURE: Occurrence of botulism and implication of a particular food as the vehicle causing this outbreak. RESULTS: Nine (43%) of 21 bus drivers developed botulism, presenting with gastroenteritis, symptoms of acute cranial nerve dysfunction including ptosis, dysphagia, blurred vision, and motor weakness. One driver experienced respiratory failure. Type A toxin was detected from 3 of 9 patients' serum samples. All drivers received botulism antitoxin; there were no fatalities. Consumption of matambre (Argentine meat roll) was significantly associated with illness. Among 11 persons who ate matambre, 9 developed illness, compared with none of those who did not eat it (P<.001). The matambre had been cooked in water at 78 degrees C to 80 degrees C for 4 hours, sealed in heat-shrinked plastic wrap, and stored in refrigerators that did not cool adequately. Subsequently, a botulism surveillance and antitoxin release system was established. CONCLUSIONS: Insufficient cooking time and temperatures, storage in heat-shrinked plastic wrap, and inadequate refrigeration likely contributed to Clostridium botulinum spore survival, germination, and toxin production. A rapid-response botulism surveillance and antitoxin release system in Argentina should provide more timely distribution of antitoxin to patients and may serve as a model for other nations.
Subject(s)
Botulinum Antitoxin , Botulism/epidemiology , Clostridium botulinum/isolation & purification , Communicable Disease Control/organization & administration , Disease Outbreaks , Meat/microbiology , Adult , Argentina/epidemiology , Botulinum Antitoxin/therapeutic use , Botulism/drug therapy , Botulism/prevention & control , Cohort Studies , Food Contamination , Food Handling , Humans , Male , Pharmaceutical Preparations/supply & distributionABSTRACT
The aim of this study was to determine whether psychological intervention had a beneficial effect on the quality of life and behaviour of women diagnosed with breast cancer. 36 consecutive patients with non-metastatic breast cancer assigned to surgery and systemic chemotherapy were randomised to receive either psychological intervention (weekly cognitive individual psychotherapy and bimonthly family counselling) or standard follow-up. Personality (16-PF and IIQ), quality of life (FLIC), and depression (BDI) scores were the endpoints for this study, and the questionnaires were completed by the patients at diagnosis, and up to 9 months after diagnosis. Cognitive psychotherapy and family counselling improved both depression and quality of life indexes compared with the control group. Better emotional coping behaviours were also revealed by some changes in personality traits in the intervention group.
Subject(s)
Breast Neoplasms/psychology , Cognitive Behavioral Therapy , Family Therapy , Quality of Life , Adult , Aged , Analysis of Variance , Breast Neoplasms/therapy , Depression , Female , Follow-Up Studies , Humans , Middle Aged , Personality Assessment , Prospective Studies , Self ConceptABSTRACT
The objective of this study was to examine whether H2 blockers represent a major teratogenic risk. This prospective cohort study was done at the Motherisk Program, a Teratology Information Service, Toronto, Canada. The subjects included 178 women who contacted Motherisk about gestational H2-blocker use, and 178 controls matched for maternal age, smoking, and heavy alcohol consumption. The main outcome measures were primary--major malformations, and secondary--pregnancy outcome, method of delivery, gestational age, prematurity, birthweight, small for gestational age infants, neonatal health problems, and developmental milestones. No increase in major malformations was found following first trimester exposure to H2 blockers [2.1% vs 3.5% (controls), mean difference (95% CI) -1.4% (-5.2, +2.4)]. No other aspects of pregnancy outcome or neonatal health differed between groups. This study suggests that H2-blocker exposure during the first trimester does not represent a major teratogenic risk.
Subject(s)
Abnormalities, Drug-Induced/etiology , Histamine H2 Antagonists/adverse effects , Adult , Child Development/drug effects , Cohort Studies , Delivery, Obstetric , Embryonic and Fetal Development/drug effects , Female , Heartburn/drug therapy , Humans , Infant, Newborn , Infant, Newborn, Diseases/etiology , Peptic Ulcer/drug therapy , Pregnancy , Pregnancy Complications/drug therapy , Pregnancy Outcome , Pregnancy Trimester, First , Prenatal Exposure Delayed Effects , Prospective Studies , Risk FactorsABSTRACT
Cultured astrocytes derived from newborn rat brain were inoculated with Junin virus (JV) to characterize their response to infection by means of their glial fibrillary acidic protein (GFAP) immunochemical profile. Samples from 1 to 11 days post-inoculation (pi), as well as matched controls, were serially harvested for GFAP labeling by peroxidase-antiperoxidase (PAP) method. It was only at day 3 that significantly greater values of GFAP staining (P < 0.05) were disclosed by three complementary approaches: image analysis, ELISA and immunoblot densitometry. Since such increase was abolished by Triton X-100 treatment, soluble GFAP fraction appeared responsible for the early though transient enhancement of GFAP immunoreactivity that followed viral inoculation.
Subject(s)
Astrocytes/metabolism , Glial Fibrillary Acidic Protein/metabolism , Hemorrhagic Fever, American/metabolism , Junin virus , Animals , Animals, Newborn , Astrocytes/virology , Cells, Cultured , Densitometry , Enzyme-Linked Immunosorbent Assay , Hemorrhagic Fever, American/virology , Image Processing, Computer-Assisted , Immunoblotting , Immunochemistry , Immunoenzyme Techniques , Rats , Rats, WistarABSTRACT
Se realizó un estudio prospectivo en 90 neonatos provenientes de madres con rotura prematura de membrana (RPM) mayor de 24h, con el objeto de establecer la incidencia de sepsis neonatal precoz (SNP), determinar su etiología y evaluar la capacidad diagnóstica de pruebas alternativas al hemocultivo; cultivo de hisopado de conducto auditivo externo, de aspirado nasofarígeo y de aspirado gástrico. En los neonatos nacidos vivos, se rigistró una incidencia del 4 por ciento (n=90) de RPM mayor de 24 h, y 6,9//(16/2293 recién nacidos vivos) padecieron SNP. La incidencia de SNP en neonatos de madres con RPM mayor de 24 h fue del 17,8 por ciento (16/90) y se distribuyó de la siguiente forma: 3,3 por ciento (3/90) asociado exclusivamente a RPM sin otro factor agravante, 5,6 por ciento (5/90) cuando se asoció la RPM a corioamnionitis y 8,9 por ciento (8/90) con prematurez. Con respecto a los agentes etiológicos de SNP, predominaron los Gram positivos y, dentro de ellos, Staphylococcus aureus. Ninguna de las pruebas evaluadas alcanzó la seguridad diagnóstica (sensibilidad más especificidad) necesaria para ser utilizada como pruebas alternativas al hemocultivo para diagnóstico de SNP por RPM mayor de 24 h. No obstante, ellas pueden ser empleadas como pruebas complementarias para contribuir a la identificación de recién nacidos de alto riesgo que hayan estado expuestos a infección del líquido amniótico o corioamnionitis (AU)
Subject(s)
Humans , Infant, Newborn , Bacterial Infections/diagnosis , Bacterial Infections/epidemiology , Bacterial Infections/etiology , Fetal Membranes, Premature Rupture/complications , Prospective Studies , IncidenceABSTRACT
Se realizó un estudio prospectivo en 90 neonatos provenientes de madres con rotura prematura de membrana (RPM) mayor de 24h, con el objeto de establecer la incidencia de sepsis neonatal precoz (SNP), determinar su etiología y evaluar la capacidad diagnóstica de pruebas alternativas al hemocultivo; cultivo de hisopado de conducto auditivo externo, de aspirado nasofarígeo y de aspirado gástrico. En los neonatos nacidos vivos, se rigistró una incidencia del 4 por ciento (n=90) de RPM mayor de 24 h, y 6,9//(16/2293 recién nacidos vivos) padecieron SNP. La incidencia de SNP en neonatos de madres con RPM mayor de 24 h fue del 17,8 por ciento (16/90) y se distribuyó de la siguiente forma: 3,3 por ciento (3/90) asociado exclusivamente a RPM sin otro factor agravante, 5,6 por ciento (5/90) cuando se asoció la RPM a corioamnionitis y 8,9 por ciento (8/90) con prematurez. Con respecto a los agentes etiológicos de SNP, predominaron los Gram positivos y, dentro de ellos, Staphylococcus aureus. Ninguna de las pruebas evaluadas alcanzó la seguridad diagnóstica (sensibilidad más especificidad) necesaria para ser utilizada como pruebas alternativas al hemocultivo para diagnóstico de SNP por RPM mayor de 24 h. No obstante, ellas pueden ser empleadas como pruebas complementarias para contribuir a la identificación de recién nacidos de alto riesgo que hayan estado expuestos a infección del líquido amniótico o corioamnionitis
Subject(s)
Humans , Infant, Newborn , Bacterial Infections/diagnosis , Fetal Membranes, Premature Rupture/complications , Incidence , Bacterial Infections/epidemiology , Bacterial Infections/etiology , Prospective StudiesABSTRACT
Twenty-eight patients with stage IIIB-IV non-small-cell lung cancer were treated with mitomycin C, vinblastine and cisplatin (MVP) in a phase II--minimax 2-stage design--randomized trial (with cisplatin plus etoposide as control arm). As indicated by the study design, the accrual was stopped after the 11th responder, and the combination was considered as active at the 40% level. Forty-six percent of patients had an improvement of their initial Karnofsky performance score, lasting a median of 24 weeks, and about 38% had a complete relief of symptoms. Hematologic toxicity was moderate to severe in about 50% of patients, and neurologic toxicity in about 18%; no grade 4 toxicity was observed. The estimated median progression-free survival was of 25 weeks. The observed activity and manageability, together with the positive effect on patient quality of life, account for a positive evaluation of MVP as a palliative treatment in advanced non-small-cell lung cancer.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Squamous Cell/drug therapy , Lung Neoplasms/drug therapy , Adenocarcinoma/drug therapy , Adenocarcinoma/pathology , Adult , Aged , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Squamous Cell/pathology , Cisplatin/administration & dosage , Cisplatin/adverse effects , Etoposide/administration & dosage , Female , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Mitomycins/administration & dosage , Mitomycins/adverse effects , Neoplasm Staging , Quality of Life , Remission Induction , Vinblastine/administration & dosage , Vinblastine/adverse effectsABSTRACT
In order to evaluate the diagnostic usefulness of coadjuvant tests such as external auditory canal swab culture and cultures from nasopharyngeal and gastric aspirates, and to determine the incidence and etiology of early neonatal sepsis (ENS) at our Unit, 90 newborn cases whose mothers experienced premature rupture of the membranes (PRM) were studied prospectively. Although a firm diagnosis requires positive blood cultures, the difficulty in recovering microorganisms and the trauma induced by sample collection in the baby justify the search for alternative diagnostic tests. Out of 2293 childbirths during 1991, 90 mothers (4%) had PRM more than 24 hours pre-partum, while 6.9/1000 (16/2293) developed ENS. In newborns from PMR mothers, ENS percentage was 3.3%, but increased to 5.5% in association with chorionamnionitis and reached 8.8% in premature cases. Among etiological ENS agents, Gram-positive microorganisms predominated (Table 1), particularly Staphylococcus aureus. Despite the finding that none of the coadjuvant assays (Table 2) had sufficient sensitivity or positive predictive value to identify all septic cases, they may prove useful to pinpoint newborns at high risk due to amniotic fluid exposure to infection or to chorioamnionitis.
Subject(s)
Bacterial Infections/epidemiology , Argentina/epidemiology , Bacterial Infections/diagnosis , Bacterial Infections/etiology , Female , Fetal Membranes, Premature Rupture/epidemiology , Humans , Incidence , Infant, Newborn , Pregnancy , Prospective StudiesABSTRACT
In order to evaluate the diagnostic usefulness of coadjuvant tests such as external auditory canal swab culture and cultures from nasopharyngeal and gastric aspirates, and to determine the incidence and etiology of early neonatal sepsis (ENS) at our Unit, 90 newborn cases whose mothers experienced premature rupture of the membranes (PRM) were studied prospectively. Although a firm diagnosis requires positive blood cultures, the difficulty in recovering microorganisms and the trauma induced by sample collection in the baby justify the search for alternative diagnostic tests. Out of 2293 childbirths during 1991, 90 mothers (4
) had PRM more than 24 hours pre-partum, while 6.9/1000 (16/2293) developed ENS. In newborns from PMR mothers, ENS percentage was 3.3
, but increased to 5.5
in association with chorionamnionitis and reached 8.8
in premature cases. Among etiological ENS agents, Gram-positive microorganisms predominated (Table 1), particularly Staphylococcus aureus. Despite the finding that none of the coadjuvant assays (Table 2) had sufficient sensitivity or positive predictive value to identify all septic cases, they may prove useful to pinpoint newborns at high risk due to amniotic fluid exposure to infection or to chorioamnionitis.
ABSTRACT
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) applied to outer membrane protein (OMP), extracted by a micromethod, was employed to subtype H. influenza b type I. A total of 37 H. influenzae b strains were isolated from children under 4 years of age, either with lower acute respiratory infection (LARI), or asymptomatic carriers matched according sex, socioeconomic level and seasonality. Twenty seven out of the 37 H. influenzae b strains belonged to biotype I. On the basis of OMP profiles, these 27 were classified into 8 subtypes (Figs. 2, 3, 4 and 5). The probability of two randomly chosen isolates having different OMP profiles was 0.733. The subtype termed "a" showed the greatest relative frequency and was detected both in invasive strains and in those isolated from throat samples of LARI cases and healthy children. The use of 14% SDS-PAGE allowed de detection either of a 51kD or a 49kD, as well as 25-40kD proteins, in a single run (Fig. 1). Most subtype profiles showed the 51 kD protein. Growth conditions and extraction of OMPs by our modified micromethod provide a single and inexpensive procedure within the means of the average clinical laboratory. Besides, this test is much less time-consuming than classical assays. Jointly, biotyping , serotyping and OMP profile determination, proved a useful epidemiological tool to survey H. influenzae b infection.